Goldman Sachs
AMRI

Goldman Sachs’s Albany Molecular Research Inc AMRI Stock Holding History

Goldman Sachs’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$651K – 7080
2017
Q2 		$651K Buy
+30,000
New +$544K ﹤0.01% 4857

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Goldman Sachs's AMRI Position: Q3 2017 in Review

Goldman Sachs sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 218,946 shares — an estimated $4.75M sold.

Goldman Sachs first reported a position in AMRI in Q3 2013 and held it in 16 quarters. The position peaked at $33.1M in Q2 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Goldman Sachs reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 218,946 Albany Molecular Research Inc shares in Q3 2017, an estimated $4.75M.
  • Goldman Sachs first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 16 quarters.
  • Goldman Sachs's Albany Molecular Research Inc position peaked at $33.1M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.